Modern Healthcare News
 
RSS feed

Gilead Sciences news and information

News
Generic drugs, low enrollment dampened Medicare Part D spending: CBO
By Bob Herman | July 30, 2014 | Basic Web Basic Web Subscription Details
The cost of Medicare Part D, the federal prescription drug program, has been far lower than originally predicted, new data from the Congressional Budget Office show. A massive slowdown in drug spending growth and low participation in the program have played the biggest roles.
FULL STORY »
 

Vital Signs
Sovaldi likely to cost Medicare billions
By Virgil Dickson | July 29, 2014
The rising cost of hepatitis C drugs like Sovaldi and Olysio will increase Medicare Part D spending by $2.9 billion to $5.8 billion next year and could drive up premiums as much as 8.6%, according to a new report by the actuarial firm Milliman.
FULL STORY »
 

Magazine
Sovaldi fuels earnings jump for Gilead
By Virgil Dickson | July 26, 2014 | Print Magazine Print Magazine Subscription Details
Gilead Sciences' second-quarter earnings blew through year-ago levels, thanks in part to its blockbuster, controversial hepatitis C drug Sovaldi.
FULL STORY »
 

News
Gilead reports massive Q2 earnings jump thanks to Sovaldi
By Virgil Dickson | July 23, 2014 | Basic Web Basic Web Subscription Details
Gilead Science's second-quarter earnings blew through year-ago levels, thanks in part to its blockbuster, and controversial, hepatitis C drug Sovaldi.
FULL STORY »
 

Information
HIV pills show more promise to prevent infection
By Associated Press | July 22, 2014
There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.
FULL STORY »
 


Advertisement | View Media Kit

News
Senators want answers about Sovaldi's price tag
By Paul Demko | July 11, 2014 | Basic Web Basic Web Subscription Details
Sens. Ron Wyden (D-Ore.), chairman of the Finance Committee, and Chuck Grassley (R-Iowa), the ranking minority member of the Judiciary Committee, sent a letter Friday to the chairman and CEO of Sovaldi manufacturer Gilead Sciences with questions about how the drug's price was determined.
FULL STORY »
 

News
Reform makes cash tight for providers, but not pharma and payers
By Bob Herman | June 20, 2014 | Basic Web Basic Web Subscription Details
Hospitals and other providers face more financial challenges, and perhaps more near-term credit downgrades, than health insurers and pharmaceutical companies as healthcare reform unfolds, according to a new report from Standard & Poor's.
FULL STORY »
 

News
Reform Update: Pricey hepatitis C drugs strain Medicaid budgets
By Virgil Dickson | June 17, 2014 | Basic Web Basic Web Subscription Details
State officials are scrambling to control the burden of Gilead's $1,000-a-pill hepatitis drug Sovaldi, particularly in states that have agreed to cap Medicaid spending under CMS waivers.
FULL STORY »
 

News
CMS targets boomers, those at high risk for hepatitis C screenings
By Virgil Dickson | June 02, 2014 | Basic Web Basic Web Subscription Details
The CMS has finalized its coverage decision to reimburse for hepatitis C virus screenings for two target populations, including baby boomers.
FULL STORY »
 

News
AstraZeneca holding firm against Pfizer's advances
By Beth Kutscher | May 23, 2014 | Basic Web Basic Web Subscription Details
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...
FULL STORY »
 

Search ModernHealthcare.com:


 

Switch to the new Modern Healthcare Daily News app

For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.